2016
DOI: 10.1038/bjc.2015.440
|View full text |Cite
|
Sign up to set email alerts
|

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

Abstract: Background:This randomised phase II study evaluated the efficacy and safety of panitumumab added to docetaxel-based chemotherapy in advanced oesophagogastric cancer.Methods:Patients with metastatic or locally recurrent cancer of the oesophagus, oesophagogastric junction or stomach received docetaxel and a fluoropyrimidine with or without panitumumab for 8 cycles or until progression. The primary end point was response rate (RECIST1.1). We planned to enrol 100 patients, with 50% expected response rate for combi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
31
0
1

Year Published

2017
2017
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 43 publications
(32 citation statements)
references
References 18 publications
0
31
0
1
Order By: Relevance
“…As shown in Figure 1 , through extensive searching and exclusion, 23 articles with 4,109 patients were finally obtained [ 1 3 , 11 , 13 31 ]. The baseline characteristics of all included studies shown presented in Table 1 .…”
Section: Resultsmentioning
confidence: 99%
“…As shown in Figure 1 , through extensive searching and exclusion, 23 articles with 4,109 patients were finally obtained [ 1 3 , 11 , 13 31 ]. The baseline characteristics of all included studies shown presented in Table 1 .…”
Section: Resultsmentioning
confidence: 99%
“…Therefore, various EGFR-targeted drugs including monoclonal antibodies (mAbs, cetuximab and panitumumab) and tyrosine kinase inhibitors (TKIs; gefitinib and erlotinib) have been examined in the clinical for esophageal cancer patients. However, the efficacy was far from satisfactory (17)(18)(19)(20)(21). Since the crosstalk between EGFR and IGF-1R pathways exist, strategies of the dual-inhibition of both pathways have been pursued for enhanced antitumor efficacy.…”
Section: Discussionmentioning
confidence: 99%
“…Co-expression of the two receptors was observed in resected non-small cell lung cancer (NSCLC), colorectal cancer, adrenocortical carcinoma, pancreatic ductal adenocarcinoma, and was found to be associated with poor pathological stage and shorter diseasefree survival (DFS) (13)(14)(15)(16). A number of EGFR-targeted drugs (gefitinib, erlotinib, cetuximab and panitumumab) alone or in combination with chemotherapeutics have been tested clinically for the treatment of patients with esophageal cancer, but the results are disappointing (17)(18)(19)(20)(21). Different from the monoclonal antibodies and tyrosine kinase inhibitors, antibody-drug conjugates or ligand-toxin fusion proteins taking advantage of the specificity of antibodies or ligands and the potent cytotoxic activity of toxins have shown elevated antitumor efficacy.…”
Section: Introductionmentioning
confidence: 99%
“…Early phase II trials combining cetuximab, panitumumab, or erlotinib with cytotoxic chemotherapy in GEC reported first line therapy response rates ranging from 41–65%. 5154 Second line phase II evaluation of gefitinib or erlotinib monotherapy led to more modest responses of ~9–11%, and responses appeared limited to proximal EGJ cancers rather than distal GC. 55,56 …”
Section: Introductionmentioning
confidence: 99%